Tuesday - March 10, 2026

Category Archives: Science

Vitiligo Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Vitiligo Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Vitiligo pipeline landscape. It covers the Vitiligo pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Vitiligo pipeline therapeutics … Continue reading →

Lupus Nephritis Clinical Trial Pipeline Gains Momentum: 35+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Lupus Nephritis Pipeline Insight 2026” report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Lupus Nephritis pipeline landscape. It covers the Lupus Nephritis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Shop Genomics Addresses Laboratory Equipment Accessibility Crisis with Educational Resources for K-12 Science Programs

Too many students complete their K-12 education without ever handling the tools that drive modern biological research. The equipment costs and procurement complexity have been real barriers for schools wanting to offer authentic laboratory experiences. We are working to change … Continue reading →

Relapsed/Refractory Acute Myeloid Leukemia Treatment Pipeline Shows Strong Momentum as 50+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Relapsed/refractory acute myeloid leukemia Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 75+ pipeline drugs in Relapsed/refractory acute myeloid leukemia (AML) pipeline landscape. It covers the Relapsed/Refractory Acute Myeloid Leukemia pipeline drug profiles, including clinical and … Continue reading →

Refractory Multiple Myeloma Clinical Trial Pipeline Expands as 75+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Refractory Multiple Myeloma Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Refractory Multiple Myeloma pipeline landscape. It covers the Refractory Multiple Myeloma pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Pulmonary Fibrosis Clinical Trial Pipeline Shows Potential with Active Contributions from 110+ Key Companies | DelveInsight

DelveInsight’s, “Pulmonary Fibrosis Pipeline Insight 2026” report provides comprehensive insights about 110+ companies and 140+ pipeline drugs in Pulmonary Fibrosis pipeline landscape. It covers the Pulmonary Fibrosis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Psoriasis Clinical Trial Pipeline Accelerates as 65+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Psoriasis Pipeline Insight, 2026” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in the Psoriasis pipeline landscape. It covers the Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Psoriasis pipeline … Continue reading →

Crohn’s Disease Clinical Trial Pipeline Gains Momentum: 90+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Crohn’s Disease Pipeline Insight 2026” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Prostate Cancer Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Prostate Cancer Pipeline Insight 2026” report provides comprehensive insights about 140+ companies and 150+ pipeline drugs in the Prostate Cancer pipeline landscape. It covers the Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →